Search

Your search keyword '"Ji-gang Lei"' showing total 2 results
Start Over Author "Ji-gang Lei" Topic medicine.anatomical_structure
2 results on '"Ji-gang Lei"'

1. Human adipose, placenta, and umbilical cord-derived mesenchymal stem cells ameliorate imiquimod-induced psoriatic mice via reducing T cells infiltration

Author

Zhenyao Xu, Chengjie Ren, Meiping Shen, Song Xiaole, Li Suke, Ji‐gang Lei, Dai Chengxiang, Wang Jing, Li Ping, Chen Yinglu, Meng Li, and Zhikai Wang

Subjects
Pathology, medicine.medical_specialty, business.industry, Mesenchymal stem cell, Adipose tissue, Imiquimod, General Medicine, medicine.disease, Umbilical cord, medicine.anatomical_structure, Placenta, medicine, business, Infiltration (medical), medicine.drug
Published
2021

2. Preclinical efficacy and clinical safety of clinical‐grade nebulized allogenic adipose mesenchymal stromal cells‐derived extracellular vesicles

Author

Meng Li, Wang Jing, Dong Xu, Ying-gang Zhu, Dai Chengxiang, Meng-Meng Shi, Guochao Shi, Jiayang Yan, Li Suke, Xue‐mei Zhu, Ji‐gang Lei, Qing‐yuan Yang, Min Zhou, Antoine Monsel, Jie-Ming Qu, Li Ping, Jing‐ya Zhao, HAL-SU, Gestionnaire, Shanghai Jiao Tong University [Shanghai], Immunologie - Immunopathologie - Immunothérapie [CHU Pitié Salpêtrière] (I3), CHU Charles Foix [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Service d'Anesthésie réanimation [CHU Pitié-Salpêtrière], CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Departement Hospitalo- Universitaire - Inflammation, Immunopathologie, Biothérapie [Paris] (DHU - I2B), Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Centre National de la Recherche Scientifique (CNRS)-CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), University of Science and Technology Beijing [Beijing] (USTB), Cellular Biomedicine Group Inc. (CBMG), and Fudan University [Shanghai]

Subjects
Adult, Male, Histology, Stromal cell, Adolescent, Cell- and Tissue-Based Therapy, Drug Evaluation, Preclinical, Inflammation, Therapeutics, Pharmacology, Lung injury, Young Adult, Therapeutic index, medicine, Animals, Humans, Pseudomonas Infections, lung injury, Survival rate, Research Articles, Mice, Inbred BALB C, [SDV.MHEP] Life Sciences [q-bio]/Human health and pathology, Lung, medicine.diagnostic_test, QH573-671, business.industry, nebulization, Mesenchymal stem cell, Mesenchymal Stem Cells, Cell Biology, Middle Aged, Mice, Inbred C57BL, Survival Rate, Disease Models, Animal, Bronchoalveolar lavage, medicine.anatomical_structure, healthy volunteers, Pseudomonas aeruginosa, Cytokines, Female, Patient Safety, medicine.symptom, business, extracellular vesicles, mesenchymal stromal cells, Cytology, Bronchoalveolar Lavage Fluid, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology, Research Article
Abstract

Mesenchymal stromal cell‐derived extracellular vesicles (MSC‐EVs) turn out to be a promising source of cell‐free therapy. Here, we investigated the biodistribution and effect of nebulized human adipose‐derived MSC‐EVs (haMSC‐EVs) in the preclinical lung injury model and explored the safety of nebulized haMSC‐EVs in healthy volunteers. DiR‐labelled haMSC‐EVs were used to explore the distribution of nebulized haMSC‐EVs in the murine model. Pseudomonas aeruginosa‐induced murine lung injury model was established, and survival rate, as well as WBC counts, histology, IL‐6, TNF‐α and IL‐10 levels in bronchoalveolar lavage fluid (BALF) were measured to explore the optimal therapeutic dose of haMSC‐EVs through the nebulized route. Twenty‐four healthy volunteers were involved and received the haMSC‐EVs once, ranging from 2 × 108 particles to 16 × 108 particles (MEXVT study, {"type":"clinical-trial","attrs":{"text":"NCT04313647","term_id":"NCT04313647"}}NCT04313647). Nebulizing haMSC‐EVs improved survival rate to 80% at 96 h in P. aeruginosa‐induced murine lung injury model by decreasing lung inflammation and histological severity. All volunteers tolerated the haMSC‐EVs nebulization well, and no serious adverse events were observed from starting nebulization to the 7th day after nebulization. These findings suggest that nebulized haMSC‐EVs could be a promising therapeutic strategy, offering preliminary evidence to promote the future clinical applications of nebulized haMSC‐EVs in lung injury diseases.

Published
2021

Catalog

Books, media, physical & digital resources
See catalog results